Table of Content

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview
Introduction
Advantages of Protein PEGylation
Limitations of PEGylated Therapeutics

Chapter 3 Market Dynamics
Market Dynamics Snapshot
Market Drivers
Protein Drugs in Hematology and Oncology
Design of Biobetters
Market Restraints
Immunogenicity and Side Effects
Formulation Challenges
Market Opportunities
Site-Specific PEGylation
New Indications and Formulation Techniques

Chapter 4 Emerging Technologies and Developments
Introduction
Non-Covalent PEGylation
PEGylation of Nanoparticles
Antibody-Drug Conjugates (ADCs)

Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Global PEGylated Proteins Market, by Protein Type
Granulocyte-Colony Stimulating Factors (G-CSF)
PEGylated Monoclonal Antibodies
PEGylated Interferons
PEGylated Recombinant Factors
Other Protein Types
Global PEGylated Proteins Market, by PEGylation Type
Linear PEGylated Proteins
Branched PEGylated Proteins
Global PEGylated Proteins Market, by PEGylation Application
Autoimmune Diseases
Hematology
Cancer
Other Applications
Geographic Breakdown
Global Market for PEGylated Proteins, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 6 Competitive Intelligence
Recent Developments in the PEGylated Proteins Market
Clinical Trial Activities

Chapter 7 Sustainability in the PEGylated Proteins Market: ESG Perspective
Introduction
Sustainability in the PEGylated Proteins Industry
Understanding the ESG Data
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC
Chapter 8 Appendix
Methodology
Sources
Abbreviations
Company Profiles
AMGEN INC.
F. HOFFMANN-LA ROCHE LTD.
MERCK KGAA
PFIZER INC.
SANDOZ GROUP AG



List of Figures


Summary Figure : Global Market for PEGylated Proteins, by Region, 2020-2028
Figure 1 : Advantages of Protein PEGylation
Figure 2 : Timeline of PEGylated Protein Therapeutics
Figure 3 : Disadvantages of PEGylated Protein Therapeutics
Figure 4 : Market Dynamics of Global PEGylated Proteins
Figure 5 : Emerging Technologies in the PEGylated Proteins Market
Figure 6 : Global Market Shares of PEGylated Proteins, by Protein Type, 2022
Figure 7 : Global Market for G-CSF, by Region, 2020–2028
Figure 8 : Global Market for PEGylated mAbs, by Region, 2020-2028
Figure 9 : Global Market for PEGylated Interferons, by Region, 2020-2028
Figure 10 : Global Market for PEGylated Recombinant Factors, by Region, 2020-2028
Figure 11 : Global Market for Other Protein Types, by Region, 2020-2028
Figure 12 : Global Market Shares of PEGylated Proteins, by PEGylation Type, 2022
Figure 13 : Global Market for Linear PEGylated Proteins, 2020-2028
Figure 14 : Global Market for Linear PEGylated Proteins, by Region, 2020–2028
Figure 15 : Global Market for Branched PEGylated Proteins, 2020-2028
Figure 16 : Global Market for Branched PEGylated Proteins, by Region, 2020-2028
Figure 17 : Global Market Shares of PEGylated Proteins, by Application, 2022
Figure 18 : Global Market for PEGylated Proteins for Autoimmune Diseases, 2020-2028
Figure 19 : Global Market for PEGylated Proteins for Autoimmune Diseases, by Region, 2020–2028
Figure 20 : Global Market for PEGylated Proteins for Hematology, 2020-2028
Figure 21 : Global Market for PEGylated Proteins for Hematology, by Region, 2020–2028
Figure 22 : Global Market for PEGylated Proteins for Cancer, 2020-2028
Figure 23 : Global Market for PEGylated Proteins for Cancer, by Region, 2020-2028
Figure 24 : Global Market for PEGylated Proteins for Other Applications, 2020-2028
Figure 25 : Global Market for PEGylated Proteins for Other Applications, by Region, 2020–2028
Figure 26 : Global Market Shares of PEGylated Proteins, by Region, 2022
Figure 27 : Global Market for PEGylated Proteins, by Region, 2020-2028
Figure 28 : North American Market Shares of PEGylated Proteins, by Country, 2022
Figure 29 : European Market Shares of PEGylated Proteins, by Country, 2022
Figure 30 : Asia-Pacific Market Shares of PEGylated Proteins, by Country, 2022
Figure 31 : Snapshot of ESG Pillars
Figure 32 : Advantages of ESG for Companies
Figure 33 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 34 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 35 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 36 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 37 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 38 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 39 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 40 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2023
Figure 41 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2023

List of Tables

 

Summary Table : Global Market for PEGylated Proteins, by Region, Through 2028
Table 1 : PEGylated Drugs in Clinical Trials for Cancer
Table 2 : Discontinued PEGylated Drugs in Clinical Trials
Table 3 : Side Effects Observed with Approved Products
Table 4 : Global Market for PEGylated Proteins, by Protein Type, Through 2028
Table 5 : Marketed PEGylated G-CSF Drugs
Table 6 : Global Market for G-CSF, by Region, Through 2028
Table 7 : Global Market for PEGylated mAbs, by Region, Through 2028
Table 8 : Global Market for PEGylated Interferons, by Region, Through 2028
Table 9 : Global Market for PEGylated Recombinant Factors, by Region, Through 2028
Table 10 : Global Market for Other Protein Types, by Region, Through 2028
Table 11 : Global Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 12 : Global Market for Linear PEGylated Proteins, by Region, Through 2028
Table 13 : Global Market for Branched PEGylated Proteins, by Region, Through 2028
Table 14 : Global Market for PEGylated Proteins, by Application, Through 2028
Table 15 : Global Market for PEGylated Proteins for Autoimmune Diseases, by Region, Through 2028
Table 16 : Global Market for PEGylated Proteins for Hematology, by Region, Through 2028
Table 17 : Global Market for PEGylated Proteins for Cancer, by Region, Through 2028
Table 18 : Global Market for PEGylated Proteins for Other Applications, by Region, Through 2028
Table 19 : Global Market for PEGylated Proteins, by Region, Through 2028
Table 20 : North American Market for PEGylated Proteins, by Country, Through 2028
Table 21 : North American Market for PEGylated Proteins, by Protein Type, Through 2028
Table 22 : North American Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 23 : North American Market for PEGylated Proteins, by Application, Through 2028
Table 24 : European Market for PEGylated Proteins, by Country, Through 2028
Table 25 : European Market for PEGylated Proteins, by Protein Type, Through 2028
Table 26 : European Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 27 : European Market for PEGylated Proteins, by Application, Through 2028
Table 28 : Asia-Pacific Market for PEGylated Proteins, by Country, Through 2028
Table 29 : Asia-Pacific Market for PEGylated Proteins, by Protein Type, Through 2028
Table 30 : Asia-Pacific Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 31 : Asia-Pacific Market for PEGylated Proteins, by Application, Through 2028
Table 32 : RoW Market for PEGylated Proteins, by Protein Type, Through 2028
Table 33 : RoW Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 34 : RoW Market for PEGylated Proteins, by Application, Through 2028
Table 35 : Recent Developments in PEGylated Proteins Market, 2022 and 2023
Table 36 : Competitor Clinical Trial Activities in PEGylated Protein Therapeutics, by Phase, 2023
Table 37 : ESG Risk Rankings for Major PEGylated Protein Drug Companies*
Table 38 : ESG: Environmental Overview
Table 39 : ESG: Social Overview
Table 40 : ESG: Governance Overview
Table 41 : Report Sources
Table 42 : Abbreviations Used in this Report
Table 43 : Amgen Inc.: Company Snapshot
Table 44 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 45 : Amgen Inc.: Product Portfolio
Table 46 : Amgen Inc.: News/Key Developments, 2023
Table 47 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 48 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 49 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 50 : Merck KGaA: Company Snapshot
Table 51 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 52 : Merck KGaA: Product Portfolio
Table 53 : Merck KGaA: News/Key Developments, 2022 and 2023
Table 54 : Pfizer Inc.: Company Snapshot
Table 55 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 56 : Pfizer Inc.: Product Portfolio
Table 57 : Pfizer Inc.: News/Key Developments, 2023
Table 58 : Sandoz Group AG: Company Snapshot
Table 59 : Sandoz Group AG: Financial Performance, FY 2022 and 2023
Table 60 : Sandoz Group AG: Product Portfolio
Table 61 : Sandoz Group AG: News/Key Developments, 2023